Replies to post #238612 on Avid Bioservices Inc (CDMO)

[cjgaddy]

CFH, gotta head out – the answer to your question is probably somewhere in the 6-2013/ASCO FINAL Results PDF...
http://www.peregrineinc.com/images/stories/pdfs/2013_asco_nsclc.pdf

More: 6-3-13/ASCO’13: Final Data Ph.II 2L/NSCLC http://tinyurl.com/my8qxw7
…60% improvement in MOS: Bavi/3mg=11.7mos. vs. 7.3mos. for CTL-arm(combined Bavi/1mg + DoxyOnly arms), HR=.662, P=.113

6-3-13: "Immunotherapies have shown significant promise in treating solid tumors and it is encouraging to see these latest results from bavituximab in 2nd-line NSCLC. Bavituximab is a unique targeted immunotherapy with a novel mechanism of action that potentially synergizes well with other compounds currently being developed for oncology," said Martin J. Edelman, M.D., Professor of Medicine at the University of Maryland Greenebaum Cancer Center [ http://medschool.umaryland.edu/facultyresearchprofile/viewprofile.aspx?id=6214 ]. "I look forward to being involved in the upcoming Phase III trial and to seeing the potential of bavituximab in other indications and combinations."